TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03490253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIAMANTE Adaptive
Description: In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIAMANTE Static
Description: The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
Study: NCT04820738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor training exercises
Description: Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Sensorimotor training exercises
Description: Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
Study: NCT03253380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients
Description: Early rehabilitation of MV patients in the respiratory ICU
Study: NCT03355872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: Biosimilar of Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HLX01
Description: Biosimilar of Rituximab
Study: NCT04140942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study: NCT00951587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ (Capsule Endoscopy)
Description: Medical Device
Study: NCT02812823

Intervention type: DEVICE
Group type: OTHER
Intervention: High-resolution anorectal manometry
Description: Recording of conventional manometric parameters after insertion of the catheters.
Study: NCT00719355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Description: Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
Study: NCT02726724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 observers
Study: NCT03077074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low carbohydrate consumption
Description: consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
Study: NCT02535858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart and respiratory rate and VE
Description: To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart and respiratory rate and video
Description: Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
Study: NCT00656942

Intervention type: DEVICE
Intervention: Quantitative Sensory Testing (QST)
Description: QST consists of a series of heat and cold stimulation tests.

Intervention type: DEVICE
Intervention: Quantitative Sensory Testing (QST)
Description: QST consists of a series of heat and cold stimulation tests.

Intervention type: DEVICE
Intervention: Quantitative Sensory Testing (QST)
Description: QST consists of a series of heat and cold stimulation tests.
Study: NCT01728675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform two isokinetic eccentric exercise bouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform two isokinetic eccentric exercise bouts
Study: NCT03603626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Preemptive pregabalin 150 mg administered 1 hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo administered 1 hour before surgery
Study: NCT00038025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycoformycin (DCF)
Description: Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
Study: NCT03021681

Intervention type: OTHER
Group type: OTHER
Intervention: autologous bronchial basal cell transplantation
Description: the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
Study: NCT02851017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
Study: NCT04428034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Skills Together
Description: Information provided in arm/group description.
Study: NCT02194361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthocyan capsules
Description: Bilberry extract capsules, 160 mg (25% anthocyanosides)
Study: NCT03293147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPLC-MS/MS-guided intervention
Description: The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
Study: NCT02194361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03524651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Blisters of 10 capsules containing 150 mg of ferrous sulfate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fe-ASP
Description: Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fe-ASP
Description: Blisters of 10 capsules containing inactive ingredients of Microfer.
Study: NCT03806673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine
Description: epidural block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine
Description: epidural block
Study: NCT03076632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical plus transcranial stimulation
Description: Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical plus transcranial stimulation
Description: Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
Study: NCT03293147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for hypertensive patients
Study: NCT03007732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
Study: NCT01341106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with entecavir(Baraclude®)
Description: Patient will be daily treated with 1 tablet of entecavir per oral
Study: NCT03007732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: 5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: 5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
Study: NCT03076632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical plus transcranial stimulation
Description: Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stimulation plus hand/wrist exercise
Description: Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stimulation plus hand/wrist exercise
Description: Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stimulation plus hand/wrist exercise
Description: Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyographic (EMG)-triggered (closed-loop) stimulation
Description: Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyographic (EMG)-triggered (closed-loop) stimulation
Description: Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
Study: NCT04688385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multipeptide Vaccine+ XS15
Description: Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
Study: NCT02726724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 observer
Study: NCT01079416

Intervention type: DEVICE
Intervention: Capsule endoscopy, Esophagogastroduodenoscopy
Study: NCT03910218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCM4HIV
Description: Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
Study: NCT00812773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: Investigational Product
Study: NCT03910218

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
Study: NCT02832986

Intervention type: OTHER
Intervention: Medical Questionary
Description: The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment
Study: NCT04815005

Intervention type: OTHER
Intervention: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Description: Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
Study: NCT04532749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Participants will receive Seltorexant tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets.
Study: NCT01848769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 pMDI + AC Plus
Description: Four inhalations for a total dose of BDP/FF 200/24 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP + AC Plus
Description: Four inhalations for a total dose of BDP 200 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol + AC Plus
Description: Four inhalations for a total dose of Formoterol 24 mcg
Study: NCT00526214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib medication
Description: In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
Study: NCT02551601

Intervention type: OTHER
Intervention: measure subfoveal choroidal thickness
Description: measure subfoveal choroidal thickness using optical coherence tomography
Study: NCT04471506

Intervention type: OTHER
Group type: OTHER
Intervention: interval training
Description: Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).

Intervention type: OTHER
Group type: OTHER
Intervention: diet recommendations
Description: the control group will follow diet recommendations for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: diet recommendations
Description: the control group will follow diet recommendations for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: mindfulness breathing
Description: Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
Study: NCT03084601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide, Iodoform, paste
Description: mixture of calcium hydroxide and iodoform

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-mixtatin
Description: 3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
Study: NCT02826005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT00638950

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 LC-PUFA
Description: Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo products were commercial dairy products with comparable fat contents.
Study: NCT02530034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02908594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Exercise Peddler 3000, Medi-Bike, Taiwan
Description: A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes.
Study: NCT02545465

Intervention type: DRUG
Intervention: Riociguat (Adempas, BAY63-2521)
Description: As per the treating physicians discretion
Study: NCT02434666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC-201
Study: NCT01114191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 400 mg days 6-11
Study: NCT04130633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vapor (distilled water)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Pure THC vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor
Study: NCT04259008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manganese omission
Description: Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 mCg/kg/day manganese from Multitrace-4 Neonatal.
Description: 5 mCg/kg/day manganese from Multitrace-4 Neonatal.
Study: NCT00731146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Minimum Effective Anesthetic Volume
Description: Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
Study: NCT05811000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM012
Description: PM012 650 mg tablet drug
Study: NCT04130633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Pinene
Description: Pure alpha-pinene vapor
Study: NCT05811000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM012
Description: PM012 650 mg tablet drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM012
Description: PM012 650 mg tablet drug
Study: NCT04298229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
Study: NCT00731146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Stimulator Minimum Effective Anesthetic Volume
Description: Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
Study: NCT05811000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PM012 Placebo
Description: PM012 tablet placebo
Study: NCT04298229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized Diuretic Therapy
Description: Structured usual care arm with protocolized diuretic therapy based on urine output.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized Diuretic Therapy
Description: Structured usual care arm with protocolized diuretic therapy based on urine output.
Study: NCT04642326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Group: experimental - UVC Therapy applied
Description: in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
Study: NCT01556503

Intervention type: DEVICE
Intervention: VivaScope System
Description: VivaScope System, Model#s 1500 and 2500